There are Magneto- and electro-encephalography (M/EEG) have been included in four UK-based cohort studies of AD dementia and AD-risk.  He we review these closely aligned studies and their interim results, spanning (i) the Cambridge centre for Ageing and Neuroscience, CamCAN, a population based lifespan ageing study; (ii) CamCAN study of cognitively frail adults (iii) the MRC Deep and Frequent Phenotyping Study, DFP, with preclinical Amyloid-positive oder adults and (iv) the longitudinal New Therapeutics for Alzheimers disease study, NTAD, with symptomatic AD (MCI or early dementia, Amyloid-positive) and controls. Together, these studies enable one to determine the M/EEG signatures of AD, and identify M/EEG biomarkers that indicate the presence, severity, and prognosis of AD pathology. DFP and NTAD studies combined their M/EEG data with plasma and CSF biomarkers (including pT217, pT181, NFL, GFAP).  NTAD has additional 11C-UCBJ PET imaging for synaptic density. We will consider the choice of tasks in MEG, including episodic memory, paired associates learning, oddball tasks and resting-state.  We will discuss the tasks’ tradeoff in tolerance, confounds and scalability and phenomenological relevance to symptoms in the context of AD. We will review the evidence for test-retest the reliability of evoked and induced responses, an essential precursor to the adoption of M/EEG studies into early phase clinical trials. And the relationship between M/EEG measures, UCBJ PET, and fluidic biomarkers like pT217 and NULISA. Through the presentation, you will learn about advances in M/EEG, and the decisions required when considering the adoption of M/EEG into clinical trials.